General
Preferred name
CHLORPROMAZINE
Synonyms
ML171 Analog ()
CHLORPROMAZINE HYDROCHLORIDE ()
3-(2-Chloro-10h-phenothiazin-10-yl)-n,n-dimethylpropan-1-amine ()
Chlorpromazine (D6 hydrochloride) ()
Chlorpromazine HCl ()
Sonazine ()
CPZ ()
Chlorpromazine (HCl) ()
Chlorpromazine69-09-0 ()
Chlorpromazine (hydrochloride) ()
Chlorpromazine-d6 (hydrochloride) ()
Nci-c05210 ()
Chlorpromazini hydrochloridum ()
Largactil ()
Klorproman ()
Promapar ()
NSC-17479 ()
Largactil Fte ()
Thorazine ()
Chlorazine ()
Chlorpromazine Hydrochloride Intensol ()
Rimazine ()
Norcozine ()
Marazine ()
Chloractil ()
NSC-226514 ()
Wintermin ()
Chlorpromazinum ()
Fenactil ()
Esmind ()
Chlorpromazine tannate ()
Elmarin ()
Megaphen ()
NSC-167745 ()
Chlorpromazine hibenzate ()
Sanopron ()
Chlorpromazine phenolphthalinate ()
Novomazina ()
Largactilothiazine ()
J2.794D ()
Propaphenin ()
SKF-2601A ()
Aminazine ()
P&D ID
PD010004
CAS
69-09-0
50-53-3
34468-21-8
1228182-46-4
Tags
natural product
drug
nuisance
obsolete probe
available
Approved by
FDA
First approval
1957
Drug indication
Severe acute respiratory syndrome (SARS)
Anti-Emetic
Middle East Respiratory Syndrome (MERS)
Schizophrenia
Antipsychotic
Drug Status
investigational
vet_approved
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Chlorpromazine was the first antipsychotic drug to be discovered. It is one of the most sedating of the typical antipsychotics and also causes antimuscarinic effects. (GtoPdb)
MOA Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).; Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. This action could also account for psychomotor agitation and amplification of psychosis (very rarely noted in clinical use).
DESCRIPTION Dopamine receptor antagonist; anti-emetic; antipsychotic (LOPAC library)
DESCRIPTION Chlorpromazine is a low-potency typical antipsychotic agent that is used to treat psychotic disorders. Chlorpromazine exerts its antipsychotic effect by blocking postsynaptic dopamine receptors in cortical and limbic areas of the brain, thereby preventing the excess of dopamine in the brain. This leads to a reduction in psychotic symptoms, such as hallucinations and delusions. (BOC Sciences Bioactive Compounds)
Cell lines
5
Organisms
12
Compound Sets
34
AdooQ Bioactive Compound Library
A10206
BOC Sciences Bioactive Compounds
chlorpromazine-cas-50-53-3-item-12156
Cayman Chemical Bioactives
16129
25636
ChEMBL Approved Drugs
CHEMBL1713
CHEMBL71
ChEMBL Drugs
CHEMBL1713
CHEMBL71
Concise Guide to Pharmacology 2017/18
83
Concise Guide to Pharmacology 2019/20
83
Concise Guide to Pharmacology 2021/22
83
Concise Guide to Pharmacology 2023/24
83
Drug Repurposing Hub
DrugBank
DB00477
DrugBank Approved Drugs
DB00477
DrugCentral
621
DrugCentral Approved Drugs
621
DrugMAP
DM5X7DJ
DMBGZI3
DrugMAP Approved Drugs
DMBGZI3
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
83
Ki Database
CHLORPROMAZINE
CPZ
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1713
CHEMBL71
MLSMR Probes +
NCATS Inxight Approved Drugs
U42B7VYA4P
NIH Clinical Collections (NCC)
NPC Screening Collection
Nuisance compounds in cellular assays
NURSA ligand set
nursa/index.jsf?doi=10.1621%2FKVEDIV62XD
Obsolete Compounds
chlorpromazine
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Chlorpromazine-hydrochloride(Sonazine)
chlorpromazine
TargetMol Bioactive Compound Library
T1384
The Spectrum Collection
External IDs
77
Properties
(calculated by RDKit )
Molecular Weight
318.1
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
2
cLogP
4.89
TPSA
6.48
Fraction CSP3
0.29
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
4
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
CAD
Nuisance compounds in cellular assays
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Classification
probe analog
Target
Sodium Channel
Dopamine Receptor
5-HT Receptor
Potassium Channel
5-HT2A
D2
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5
Dopamine Receptor,Potassium Channel
5-HT Receptor,Dopamine Receptor,Potassium Channel,Sodium Channel
Pathway
GPCR/G protein
Neuronal Signaling
Membrane Transporter/Ion Channel
Neuroscience
Indication
schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus
Disease Area
neurology/psychiatry, gastroenterology, hematology, infectious disease
MOA
Dopamine Receptor antagonist
Therapeutic Class
Antipsychotic Agents
Antiviral Agents
Solubility
Soluble to 64 mg/ml in DMSO.
Source data